首页> 外文期刊>Disease models & mechanisms: DMM >Vascular regression precedes motor neuron loss in the FUS (1-359) ALS mouse model
【24h】

Vascular regression precedes motor neuron loss in the FUS (1-359) ALS mouse model

机译:在FUS(1-359)ALS小鼠模型中,血管退化先于运动神经元丢失

获取原文
           

摘要

Amyotrophic lateral sclerosis (ALS) presents a poorly understood pathogenesis. Evidence from patients and mutant SOD1 mouse models suggests vascular damage may precede or aggravate motor dysfunction in ALS. We have previously shown angiogenin (ANG) treatment enhances motor neuron survival, delays motor dysfunction and prevents vascular regression in the SOD1supG93A/sup ALS model. However, the existence of vascular defects at different stages of disease progression remains to be established in other ALS models. Here, we assessed vascular integrity in vivo throughout different disease stages, and investigated whether ANG treatment reverses vascular regression and prolongs motor neuron survival in the FUS (1-359) mouse model of ALS. Lumbar spinal cord tissue was collected from FUS (1-359) and non-transgenic control mice at postnatal day (P)50, P90 and P120. We found a significant decrease in vascular network density in lumbar spinal cords from FUS (1-359) mice by day 90, at which point motor neuron numbers were unaffected. ANG treatment did not affect survival or counter vascular regression. Endogenous Ang1 and Vegf expression were unchanged at P50 and P90; however, we found a significant decrease in miRNA 126 at P50, indicating vascular integrity in FUS mice may be compromised via an alternative pathway. Our study demonstrates that vascular regression occurs before motor neuron degeneration in FUS (1-359) mice, and highlights that heterogeneity in responses to novel ALS therapeutics can already be detected in preclinical mouse models of ALS. This article has an associated First Person interview with the joint first authors of the paper .
机译:肌萎缩性侧索硬化症(ALS)的发病机理了解甚少。来自患者和突变型SOD1小鼠模型的证据表明,血管损伤可能在ALS之前或加重了运动功能障碍。我们先前已经证明,在SOD1 G93A ALS模型中,血管生成素(ANG)处理可提高运动神经元存活,延迟运动功能障碍并防止血管退化。但是,在其他ALS模型中,尚需确定疾病进展不同阶段的血管缺损。在这里,我们评估了整个疾病各个阶段的体内血管完整性,并调查了ANG治疗是否能逆转血管退化并延长ALS FUS(1-359)小鼠模型中运动神经元的存活。在出生后(P)50,P90和P120时从FUS(1-359)和非转基因对照小鼠中收集腰椎脊髓组织。我们发现到第90天时,来自FUS(1-359)小鼠的腰椎脊髓中的血管网络密度显着下降,此时运动神经元数不受影响。 ANG治疗不影响生存或抵抗血管退化。内源性Ang1和Vegf的表达在P50和P90处没有变化。然而,我们发现P50处的miRNA 126显着降低,表明FUS小鼠的血管完整性可能会通过其他途径受到损害。我们的研究表明在FUS(1-359)小鼠的运动神经元变性之前发生血管退化,并强调在临床前的ALS小鼠模型中已经可以检测到对新型ALS治疗药物的异质性。本文与论文的第一作者共同进行了第一人称采访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号